Literature DB >> 15243584

PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes.

L Larribere1, M Khaled, S Tartare-Deckert, R Busca, F Luciano, K Bille, G Valony, A Eychene, P Auberger, J P Ortonne, R Ballotti, C Bertolotto.   

Abstract

Melanocytes are cells of the epidermis that synthesize melanin, which is responsible for skin pigmentation. Transformation of melanocytes leads to melanoma, a highly aggressive neoplasm, which displays resistance to apoptosis. In this report, we demonstrate that TNF-related apoptosis-inducing ligand (TRAIL), which was thought to kill only transformed cells, promotes very efficiently apoptosis of primary human melanocytes, leading to activation of caspases 8, 9 and 3, and the cleavage of vital proteins. Further, we show that stem cell factor (SCF), a physiologic melanocyte growth factor that activates both the phosphatidyl-inositol-3 kinase (PI3K) and the extracellular regulated kinase (ERK) pathways, strongly protects melanocytes from TRAIL and staurosporine killing. Interestingly, inhibition of PI3K or its downstream target AKT completely blocks the antiapoptotic effect of SCF, while inhibition of ERK has only a moderate effect. Our data indicate that protection evoked by SCF/PI3K/AKT cascade is not mediated by an increase in the intracellular level of FLIP. Further, only a sustained PI3K activity can protect melanocytes from apoptosis, thereby indicating that the PI3K/AKT pathway plays a pivotal role in melanocyte survival. The results gathered in this report bring new information on the molecular mechanisms involved in primary melanocyte apoptosis and survival that would help to better understand the process by which melanomas acquire their resistance to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243584     DOI: 10.1038/sj.cdd.4401475

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  25 in total

1.  Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Authors:  Michael Nebozhyn; Andrey Loboda; Laszlo Kari; Alain H Rook; Eric C Vonderheid; Stuart Lessin; Carole Berger; Richard Edelson; Calen Nichols; Malik Yousef; Lalitha Gudipati; Meiling Shang; Michael K Showe; Louise C Showe
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

2.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

3.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 4.  An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer.

Authors:  Silvia von Karstedt; Henning Walczak
Journal:  Cell Death Discov       Date:  2020-03-17

5.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Authors:  N Mazurek; J C Byrd; Y Sun; M Hafley; K Ramirez; J Burks; R S Bresalier
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

6.  Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Authors:  T Botton; A Puissant; Y Cheli; T Tomic; S Giuliano; L Fajas; M Deckert; J-P Ortonne; C Bertolotto; S Tartare-Deckert; R Ballotti; S Rocchi
Journal:  Cell Death Differ       Date:  2010-07-02       Impact factor: 15.828

7.  The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis.

Authors:  Lionel Larribere; Caroline Hilmi; Mehdi Khaled; Cédric Gaggioli; Karine Bille; Patrick Auberger; Jean Paul Ortonne; Robert Ballotti; Corine Bertolotto
Journal:  Genes Dev       Date:  2005-09-01       Impact factor: 11.361

8.  TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation.

Authors:  Yunlong Huang; Nathan Erdmann; Hui Peng; Shelley Herek; John S Davis; Xu Luo; Tsuneya Ikezu; Jialin Zheng
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

Review 9.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

10.  NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

Authors:  G M De Donatis; E Le Pape; A Pierron; Y Cheli; V Hofman; P Hofman; M Allegra; K Zahaf; P Bahadoran; S Rocchi; C Bertolotto; R Ballotti; T Passeron
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.